US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Respiratory/Pulmonary Market Research Reports & Industry Analysis

RSS Feeds

Respiratory/Pulmonary Industry Research & Market Reports

1    3    5  6  7  8  9  10  
China Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in China, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Brazil Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in Brazil, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Canada Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in Canada, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Japan Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in Japan, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Germany Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in Germany, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Italy Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in Italy, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
UK Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in UK, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
US Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in US, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Russia Respiratory Drugs Market Insights - 2015
3/14/2015 | published by: Fore Pharma
... includes respiratory drugs market size estimates for 2014 in Russia, market size forecast for six years to 2020, drugs sales estimates, market share, market analysis by therapeutic sub-groups, and competitor analysis. This research helps executives ...  |  read more...
USD 1,380
Lung Cancer Partnering 2010-2015
3/1/2015 | published by: Current Partnering
... partnering deals Top lung cancer deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The Lung Cancer Partnering 2010-2015 provides understanding and access to the lung cancer partnering deals ...  |  read more...
USD 995
Respiratory Deals and Alliances of 2014
3/1/2015 | published by: Current Partnering
... during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
USD 1,495
Cough - Pipeline Review, H1 2015
2/24/2015 | published by: Global Markets Direct
... Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2015
1/22/2015 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2015
1/30/2015 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Chronic Bronchitis - Pipeline Review, H1 2015
1/30/2015 | published by: Global Markets Direct
... therapeutic development for Chronic Bronchitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Community-Acquired Bacterial Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Community-Acquired Bacterial Pneumonia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Cystic Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Cystic Fibrosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Hospital Acquired Pneumonia (HAP)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Hospital Acquired Pneumonia (HAP). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Idiopathic Pulmonary Fibrosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Idiopathic Pulmonary Fibrosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Respiratory Hypersensitivity-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Respiratory Hypersensitivity. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Respiratory Syncytial Virus (RSV) Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the Respiratory Syncytial Virus (RSV) Infections. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs ...  |  read more...
USD 2,000
Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Pneumocystis Carinii Pneumonia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Pulmonary Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Pulmonary Edema. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Pulmonary Embolism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Pulmonary Embolism. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Pulmonary Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Pulmonary Hypertension. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
1    3    5  6  7  8  9  10